Article
作者: Da, Dari F. ; Bekkering, Ezra T. ; Spruijt, Cornelia G. ; Teelen, Karina ; Nagaoka, Hikaru ; Dabire, Roch K. ; Arinaitwe, Emmanuel ; Hubregtse, Lisanne L. ; de Jong, Roos M. ; van Gemert, Geert-Jan ; van de Vegte-Bolmer, Marga ; Jore, Matthijs M. ; Stoter, Rianne ; Cohuet, Anna ; Inklaar, Maartje R. ; Vermeulen, Michiel ; Takashima, Eizo ; Tsuboi, Takafumi ; Meijer, Maartje ; Bousema, Teun ; Grievink, Sanne
Malaria transmission–blocking vaccines (TBV) target sexual stage parasites that are transmitted to mosquitoes and are critical for spread of the pathogen. The clinically most advanced TBV candidate contains part of the Pro-domain (Pro) and Domain 1 (D1) of
Plasmodium falciparum
surface protein Pfs230. Subunit vaccines that contain other domains of Pfs230 have so far failed to induce functional antibodies. Here, we produced eight single-domain fragments of Pfs230 in
Drosophila melanogaster
S2 cells and assessed their immunogenicity in mouse immunizations. In addition to D1-specific antibodies, antibodies raised against D12 showed strong functional transmission-reducing activity in membrane feeding assays with cultured parasites, an activity that was complement dependent. Murine D12-specific antibodies further reduced mosquito transmission of parasites acquired from naturally infected parasite carriers. The D12 antigen was recognized by sera from an all-age cohort of individuals who had been naturally exposed to
P. falciparum
with antibody levels increasing with age. In conclusion, we identified Pfs230D12 as a promising TBV candidate.
